For 80 years, doctors have told men with a prostate cancer history that testosterone replacement was off the table. A new randomized trial published in JAMA Internal Medicine on May 11, 2026 puts that blanket rule under serious pressure.
The SPIRIT trial — Surviving Prostate cancer while Improving quality of life through Rehabilitation with Testosterone — is the first placebo-controlled randomized evidence on TRT in prostate cancer survivors. It is not large and it is not long, but it is rigorous, and the safety signal at 24 weeks was clean.
Key Takeaways
SPIRIT randomized 136 men post-prostatectomy with low-grade disease and undetectable PSA for more than two years to testosterone cypionate 100 mg weekly or placebo
Testosterone significantly improved sexual activity, sexual desire, physical function, and aerobic performance over 24 weeks
Zero biochemical recurrences in either arm during the study window
Erectile function did not improve — radical prostatectomy damages cavernous nerves independent of hormone levels
Results apply only to men with low-grade disease, organ-confined surgery, and clean PSA more than two years out
This is a urologist-led decision, not a telehealth one
What SPIRIT Actually Tested
This was a randomized, placebo-controlled, double-blind, parallel-group trial led by Shalender Bhasin (Mass General Brigham) with sites at Johns Hopkins Hospital and Brigham and Women's Hospital. The published cohort included 136 men.
Trial Snapshot
Parameter
Detail
Population
Post-prostatectomy men with symptomatic hypogonadism
Sample size
136 randomized
Age
40 years or older
Cancer staging at surgery
Gleason 7 (3+4) or lower, pT2, N0, M0
Post-surgical PSA requirement
Undetectable for more than 2 years
Intervention
Testosterone cypionate 100 mg IM weekly for 12 weeks
Comparator
Placebo injection
Follow-up
12 weeks treatment plus 12 weeks observation
Primary endpoint
Change in sexual activity
Publication
JAMA Internal Medicine, May 11, 2026
DOI
10.1001/jamainternmed.2026.1343
The eligibility criteria matter as much as the results. SPIRIT did not test TRT in men with biochemical recurrence, higher-grade disease, positive surgical margins, or radiation therapy. The cohort represents the lowest-risk slice of prostate cancer survivors — men whose surgery looks like a cure on paper, with two-plus years of undetectable PSA to confirm it.
If your treatment history matches that profile, the data are directly relevant. If it does not, the trial does not give you an answer.
What the Data Showed
The headline findings, as reported in the trial publication and Mass General Brigham press release:
Sexual activity: significantly higher in the testosterone arm versus placebo
Sexual desire: significantly higher in the testosterone arm
Physical function: significantly improved on testosterone
Aerobic performance: significantly improved
Body composition: improved with testosterone
Well-being / quality of life: significantly improved
Erectile function: no significant difference between arms
PSA / biochemical recurrence: zero recurrences in either group during the 24-week window
That last point is the one urologists were watching for. The historical fear — based on Huggins' 1941 single-patient observation — has been that giving testosterone to a man with a prostate cancer history will reignite microscopic disease. SPIRIT did not see that signal at 24 weeks. Neither arm had a single PSA-defined recurrence. For context on the 80-year-old myth that shaped this thinking, see TRT and prostate cancer: the 80-year myth.
The Erectile Function Finding Is Important
Many men assume that if libido comes back, erections will follow. SPIRIT is a clean reminder that radical prostatectomy is mechanically separate from testosterone levels.
The cavernous nerves that drive erectile rigidity run along the prostate. Even with nerve-sparing technique, surgery damages them. Recovery happens slowly over 12 to 24 months and is incomplete in many men regardless of hormone status. Restoring testosterone fixes desire and the central nervous system arousal pathway — it does not rebuild damaged peripheral nerves.
If you are post-prostatectomy and considering TRT, plan for a multi-modal approach. Most men in this situation also need PDE5 inhibitors, vacuum erection devices, or intracavernosal injections. Our TRT and erectile dysfunction guide walks through how the layers stack.
SPIRIT is a meaningful first randomized data point, not the final word. Five honest limitations.
Short follow-up. Twenty-four weeks total. Prostate cancer recurrence after a clean two-year window can still happen years later. SPIRIT cannot rule out a longer-horizon signal. Larger, longer trials — or pooled observational cohorts — would need to confirm safety at 5 and 10 years.
Small sample. 136 men is enough to detect symptomatic benefit but underpowered to detect rare safety signals. A 1% recurrence excess in the testosterone arm would require thousands of patient-years of follow-up to surface.
Narrow eligibility. Only the cleanest slice of survivors — low-grade, organ-confined disease, surgical cure proven by two-plus years of undetectable PSA — was studied. Most men with prostate cancer in the population had higher-grade disease, positive margins, radiation, or biochemical recurrence at some point. SPIRIT does not speak to them.
Conservative dose. 100 mg weekly is on the low end of modern TRT. Whether higher maintenance doses (140 to 200 mg) would change the safety picture is unknown.
Single-arm of the cancer journey. SPIRIT tested post-prostatectomy survivors. The closely related but distinct question — TRT in men on active surveillance for prostate cancer — was not addressed and remains controversial.
How to Use This Data With Your Doctor
If you have a prostate cancer history and persistent low-T symptoms, SPIRIT is the first piece of randomized evidence you can bring to a conversation. Three practical steps.
1. Confirm You Fit the SPIRIT Profile
Pull your records and check:
Treatment: radical prostatectomy (not radiation or active surveillance)
Pathology: Gleason 7 (3+4) or lower, pT2, N0, M0
PSA history: undetectable for more than 2 years post-surgery
No biochemical recurrence at any point
Documented symptomatic hypogonadism (total T below 300 ng/dL plus symptoms)
If all five boxes check, the SPIRIT data are directly relevant. If any box does not, the trial does not yet give you an answer — but neither does it close the door. Higher-risk profiles need urologist-led case-by-case assessment.
2. See a Urologic Oncologist, Not a Telehealth Clinic
Most online TRT clinics will screen you out the moment you check the "prostate cancer history" box on intake. That is a defensible policy given the malpractice exposure. SPIRIT does not change that overnight.
If you and your urologist decide to proceed, the monitoring cadence has to be tighter than standard TRT. A defensible schedule for a post-prostatectomy SPIRIT-eligible patient:
Time Point
Tests
Baseline
Total and free testosterone, PSA, CBC, estradiol, CMP, lipids
6 weeks
Total testosterone, PSA, CBC
3 months
Total and free testosterone, PSA, CBC, estradiol
6 months
PSA, CBC, total and free testosterone
Every 3 months for year 1
PSA
Then every 3-6 months indefinitely
PSA
PSA at every visit is non-negotiable. A confirmed rising PSA at any point is a stop signal. For broader monitoring context, see TRT bloodwork schedule.
How SPIRIT Fits the Broader Evidence
SPIRIT joins a body of post-prostatectomy TRT literature that has been growing for a decade but had been observational only.
The TRAVERSE trial (5,246 men) showed TRT does not increase prostate cancer incidence in the general hypogonadal population. See TRAVERSE explained.
A 2026 MD Anderson cohort of 924 men on active surveillance found low T at baseline was associated with higher progression risk — suggesting low T is a marker, not a protector. See low T and prostate cancer progression.
Observational case series of post-prostatectomy TRT have not shown excess recurrence, but lacked randomization.
SPIRIT is the missing piece — randomized, placebo-controlled, in the exact population most likely to be denied therapy. The 24-week safety window matters less than the design quality. This is the kind of evidence guidelines committees update on.
Expect the AUA and EAU to weigh SPIRIT in their next testosterone guideline revisions. Expect more academic urologic oncology centers to begin offering structured post-prostatectomy TRT programs. Expect the most cautious online clinics to keep their screen-out policies until a 5-year safety extension publishes.
Bottom Line
SPIRIT is the strongest evidence yet that low-grade prostate cancer survivors with clean post-surgical PSA can be offered testosterone replacement safely — over 24 weeks, in a placebo-controlled randomized trial. The benefits track what TRT does in non-cancer hypogonadal men: better sexual desire, better physical function, better quality of life. The safety signal at this duration is clean.
What it does not do is rewrite the rule for everyone with a prostate cancer history. The trial cohort was narrowly selected. The follow-up was short. Longer extensions are needed. But the door has cracked open, and for men who match the SPIRIT profile, this is the data to bring to your urologist.
References
Bhasin S, Storer TW, Travison TG, et al. Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. JAMA Internal Medicine. Published online May 11, 2026. DOI: 10.1001/jamainternmed.2026.1343.
Pencina KM, Travison TG, Cunningham GR, et al. Collaborating to Improve Quality of Life Among Prostate Cancer Survivors. JAMA Internal Medicine. Published online May 11, 2026.
Mass General Brigham press release. Testosterone Treatment Improved Sexual and Physical Function for Men After Prostate Cancer Surgery. May 11, 2026.
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389:107-117.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310-320.
The SPIRIT trial randomized 136 men with hypogonadism who had undergone radical prostatectomy for low-grade prostate cancer to 12 weeks of weekly intramuscular testosterone cypionate 100 mg or placebo, with another 12 weeks of follow-up. Testosterone significantly improved sexual activity, sexual desire, physical function, and aerobic performance compared with placebo. No participant in either arm experienced biochemical recurrence during the study. Erectile function did not change. The trial was published in JAMA Internal Medicine on May 11, 2026 (DOI 10.1001/jamainternmed.2026.1343).
Is TRT actually safe after prostate cancer surgery?
SPIRIT is the first randomized placebo-controlled evidence in this population and the 24-week safety window was clean — zero biochemical recurrences in either arm. That said, 136 men over 6 months is not long enough to rule out longer-horizon recurrence risk. Eligibility was restricted to men with undetectable PSA for at least two years after prostatectomy and a Gleason score of 7 (3+4) or lower, organ-confined disease. The findings do not generalize to men with higher-grade disease, positive margins, biochemical recurrence, or active cancer.
Who was eligible for the SPIRIT trial?
Men aged 40 or older who had undergone radical prostatectomy for organ-confined prostate cancer (pT2, N0, M0) with Gleason score 7 (3+4) or lower, undetectable PSA for more than two years post-surgery, and symptomatic testosterone deficiency. Men with biochemical recurrence, higher-grade disease, or radiation therapy were excluded. If your treatment history does not match this profile, the trial results may not apply to your situation.
Does this mean I can start TRT after my prostate cancer treatment?
This is a urologist-led decision, not a telehealth clinic decision. The SPIRIT data move the conversation forward, but most online TRT clinics screen out men with any prostate cancer history. If you have a clean PSA more than two years post-prostatectomy, low-grade disease, and symptomatic hypogonadism, ask your urologic oncologist whether you fit the SPIRIT criteria and what monitoring cadence they would require. Bring the paper to the appointment.
What dose did the trial use?
Weekly intramuscular injections of testosterone cypionate 100 mg for 12 weeks. That is on the lower end of modern TRT dosing — most maintenance protocols run 120 to 160 mg per week. The conservative dose likely reflects the safety-first design in a cancer-survivor cohort.
Why didn't erectile function improve if libido did?
Radical prostatectomy damages the cavernous nerves that drive erection regardless of hormone status. The SPIRIT trial showed testosterone restored desire and sexual activity, but the mechanical capacity for erection depends on nerve-sparing surgical technique and time, not testosterone. Many post-prostatectomy men need PDE5 inhibitors, vacuum devices, or injections in addition to addressing testosterone.
